Does pulmonary artery hypertension eat law Hua Lin to be ok

summary

Pulmonary hypertension refers to pulmonary artery systolic pressure exceeding 4.00 kPa? 30 mmHg? Or mean pulmonary artery pressure exceeding 2.67 kPa? 20 mmHg?. There are many causes of pulmonary hypertension, including primary and secondary. In addition to the general treatment such as etiological treatment, weight loss, valve surgery and treatment of concomitant diseases (heart failure and hypertension), the treatment of pulmonary hypertension also includes the following specific drug treatment measures.

Does pulmonary artery hypertension eat law Hua Lin to be ok

First, calcium antagonists, such as amlodipine, can be effective in the treatment of 10% cases of pulmonary hypertension.

Second, prostacyclin: prostacyclin has long been used in the treatment of pulmonary hypertension. At present, a new prostacyclin preparation, epoprostol, has become a golden method for the treatment of pulmonary hypertension. It is especially suitable for primary pulmonary hypertension, and the effect is remarkable. For those caused by other reasons, the effect is general. However, there are still some problems in the clinical application of epoprost. In addition to central catheter administration and indwelling catheter, there are also some adverse drug reactions, such as untreated diarrhea, mandibular pain, thrombocytopenia, systemic hypertension, blushing and so on. In addition, the price of the drug is also very expensive.

Third, endothelin receptor blockers, such as bosentan, are not as effective as epoprost in improving pulmonary hypertension, and there are also some adverse reactions, such as hepatotoxicity and anemia in 30% of patients.

matters needing attention

If pulmonary hypertension is caused by repeated pulmonary embolism, anticoagulant therapy, lower extremity venous filter placement and pulmonary thrombectomy can be used. It should be noted that the mortality of thrombectomy can reach 5% - 15%. Some other new therapeutic measures, such as gene therapy, are being studied, which depends on the identification, screening and regulation of the pathogenic genes of pulmonary hypertension. Although the prospect is bright, it is not possible to apply it in clinic in a short term